Dizal Scores First JAK1 Approval For Advanced PTCL

China Nod

 
• By Dexter Jie Yan
  
first line treatment
Dizal's golidocitinib becomes world’s first approved JAK1 inhibitor for second-line PTCL • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia